Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease

NCT06409130 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

270

Enrollment

INDUSTRY

Sponsor class

Conditions

Alcohol-related Liver Disease

Interventions

DRUG: NNC0194-0499
DRUG: Semaglutide
DRUG: NNC0194-0499 placebo
DRUG: Semaglutide placebo (Group A)
DRUG: Cagrilintide + semaglutide
DRUG: Cagrilintide
DRUG: Cagrilintide placebo
DRUG: Semaglutide placebo (Group B)

Sponsor

Novo Nordisk A/S